As a first step in developing a portfolio of COVID-19 therapies, the European Commission identified five promising candidates June 29, including four monoclonal antibodies under rolling review at the EMA and an immunosuppressant that could have its marketing authorization extended to include the treatment of COVID-19 infections.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Asensus Surgical US, DNA Diagnostics Center, Eurofins Scientific, Meridian Bioscience, Newpace, Powermat Technologies, Red One Medical, Rockwell Medical.
A new study from researchers at the Washington University School of Medicine In St. Louis demonstrated evidence of a long-lasting immune response, possibly one that could last for years, from receiving Pfizer Inc.’s mRNA COVID-19 vaccine.
LONDON – New data have arrived to allay concerns about shortages of COVID-19 vaccines disrupting dosing schedules, and also answering the question of whether third – booster – doses will restore waning immunity and be effective against viral variants.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Adial, Astellas, Aurinia, Biomarin, BMS, I-Mab, Incyte, Innocare, Jazz, Lynk, Mirati, Morphosys, Nicox, RDIF, Regeneron, Samsung, Y-Mabs.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Adelia, Amydis, Bellicum, Bioeq, Cannabics, Catalyst, Crescita, Croma-Pharma, Cybin, Dydo, Galderma, Ilias, Immunitybio, Inceptua, Mass General, Medicinova, Oasmia, Orphazyme, Redhill, Sol-Gel, Teva, UNC Lineberger.